← Back to front page
Europe · Regional markets · Option Finance

Hypertension, la nouvelle arme d'AstraZeneca se précise

Published by Option Finance · France 9 h ago
Hypertension, la nouvelle arme d'AstraZeneca se précise
Option Finance

Detailed summary

Le Baxfendy d'AstraZeneca a reçu un avis favorable des experts de l'Agence européenne des médicaments, a annoncé le groupe vendredi 13 novembre. Il vise les adultes dont la…

Read the full article on Option Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (tribune-assurance.optionfinance.fr)

Also worth reading

City A.M.

Asda sales growth slowed ahead of leadership shake-up

 This is Money

Can you REALLY make money from Tropic Skincare? Here's the truth about how much sellers are paid... as the cult brand's glamorous Dragons' Den owner takes £2m in dividends

 Investors Chronicle

Rolls-Royce woos investors with £1.5bn buyback

 Finews

Lombard Odier: “We are ahead of our growth plan in the Middle East”

 MoneyWeek

The IPO catch: Why the best deals can be the hardest to buy

 Maddyness

Les startups françaises ont levé 118 millions d’euros cette semaine